奥泰生物：2025年度净利润2.18亿元，同比下降27.83%

Core Viewpoint - The company reported a total operating revenue of 911 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 5.16%. However, the net profit attributable to the parent company decreased by 27.83% to 218 million yuan, and the net profit after deducting non-recurring gains and losses fell by 34.64% to 155 million yuan [1]. Group 1: Financial Performance - The total operating revenue for 2025 was 911 million yuan, an increase of 5.16% compared to the previous year [1]. - The net profit attributable to the parent company was 218 million yuan, a decrease of 27.83% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 155 million yuan, down 34.64% from the previous year [1]. Group 2: Factors Affecting Performance - The company maintained its competitive advantages in R&D innovation, product quality, and customer service, which helped to expand sales channels and increase customer sales volume [1]. - Increased investment in new technology platforms and efforts in domestic and international market and product registrations led to a rise in R&D and sales costs compared to the previous year [1]. - Additional factors contributing to the decline in profit included increased operating costs due to U.S. government tariffs, foreign exchange losses from currency fluctuations, reduced interest income, and higher asset depreciation and amortization [1].